|
|
 |
|
Viewing report
|
|
|
|
Czech Republic Pharmaceuticals & Healthcare Report Q1 2008
Business Monitor International, Feb 2008, Pages: 59
The Czech Republic Pharmaceuticals and Healthcare Report provides independent forecasts and competitive intelligence on the Czech Republics pharmaceuticals and healthcare industry.
The drug market in the Czech Republic is showing promise, although local generics producers may struggle to cash in, in the short-term. BMI forecasts a compound growth rate (CAGR) of 6.84% for 2007- 2012. However, recent reforms have targeted older generic drugs, as the authorities attempts to constrain costs. Leading local producer Zentiva recorded a disappointing performance in the Czech Republic in H107, with sales receding 5.6% to CZK2,226mn (US$115.08mn), although BMI remains bullish about the firms prospects in the medium to long term.
Meanwhile, after much political machination, the government has managed to push through its reform agenda, which includes a programme of tax cuts aimed at slashing the country’s large fiscal burden. Reforms include the adoption of a flat-rate system for both income and corporate tax, which will eventually stand at 15% and 19% respectively. At the same time, value-added tax (VAT) will be raised to 9% from 5%. With regards to the countrys welfare system, reductions in child benefits and parental contributions will be introduced, as well as patient fees for doctor visits and hospital stays. BMI expects health expenditure to reach US$19bn by 2012, or equivalent to 8% of GDP. Although low by Western European standards, it is quite high compared with its immediate neighbours. The fiscally conservative administration is also likely to usher in a significant shift away from state health expenditure in favour of private providers.
The Czech Republic comes in second place in our revamped Business Environment Rankings. Its position is mainly due to the strength of the drug market, with per-capita spending forecast to reach US$305.4 for 2007. Patent protection, however, is a long-standing problem in the Czech Republic, due to the industry policy under the previous Communist government, which did not recognise patents on many end-products and local production of copies of Western medicines. The countrys EU membership and the adoption of pharmaceutical directives have at least in theory eased many problems related to drug copying.
Product samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
Czech Republic Pharmaceuticals and Healthcare Report Q3 2008
Czech Republic Pharmaceuticals and Healthcare Report Q3 2007
Czech Republic Pharmaceuticals and Healthcare Report Q2 2009
Czech Republic Pharmaceuticals and Healthcare Report Q4 2010
Czech Republic Pharmaceuticals and Healthcare
Mail Order and Internet Pharmacy in Europe: Embracing the New Challenge
Romania Pharmaceuticals and Healthcare Report Q4 2011
Slovakia Pharmaceuticals and Healthcare Report Q3 2008
Slovakia Pharmaceuticals and Healthcare Report Q1 2012
Market Access in Japan: New Challenges and Opportunities for the Pharmaceutical Industry
|
|
|
|
